Patent US4612282A successfully refreshed from Google Patents.
US4612282A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibodies reactive with human breast cancer
Assignee: United States Department of Health and Human Services
•
Filing: 1985-03-01
•
Granted: 1986-09-16
•
Expires: 2005-03-01
Abstract
Abstract Monoclonal antibodies demonstrating a reactivity with human breast cancer are produced. The hybridoma cultures secreting immunoglobins are produced by hydridoma technology. Splenic lymphocytes of mice, immunized with membrane-enriched fractions of metastatic human mammary carcinoma tissue are fused with the NS-1 non-immunoglobulin-secreting murine myeloma cell line. Screening of immunoglobulin reactivities and double cloning of cultures yielded 11 monoclonal antibodies that demonstrated activities with the surface of human mammary tumor cells and not with the surface of apparently normal human tissues. These monoclonal antibodies aid in the diagnosis, prognosis and treatment of human breast cancer.
Inventors
- 👤 Jeffrey Schlom
- 👤 David Colcher
- 👤 Marianna Nuti
- 👤 Patricia H. Hand
- 👤 Faye Austin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 23:14
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; C07K16/3015; A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1045; A61K51/1051; A61K2123/00; A61K38/00; G; G01; G01N; G01N2474/00; G01N2474/20
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
148 words
Antibodies from hybridoma cultures produced by the steps of (1) taking splenic lymphocytes of mice previously immunized with membrane-enriched fractions of immunoglobulin-depleted cancer cells; (2) fusing the lymphocytes with a myeloma cell line, and (3) culturing the hybridoma cell line in an in vitro culture medium or in vivo therefor to produce antibodies, which antibodies are selected from one member of the group consisting B6.2, B14.2, B39.1, F64.5,B25.2, B84.1, B38.1, B50.4 and B50.1 and which (a) react and bind with extracts from human metastatic mammary carcinoma cells from involved livers but not with liver cell extracts; (b) react and bind with at least one of the mammary carcinoma cell lines, BT-20, MCF-7, ZR-75-1, but not with lung, vulva epidermoid or oral epidermoid and not with rhabdomyosarcoma, fibrosarcoma and melanoma; and (c) do not react with normal cell derived from breast, skin, lung, bone marrow, kidney, spleen and uterus.
Claim 2
Dependent Claim
148 words
Antibodies from hybridoma cultures produced by the steps of (1) taking splenic lymphocytes of mice previously immunized with membrane-enriched fractions of immunoglobulin-depleted cancer cells; (2) fusing the lymphocytes with a myeloma cell line, and (3) culturing the hybridoma cell line in an in vitro culture medium or in vivo therefor to produce antibodies, which antibodies are selected from one member of the group consisting B6.2, B14.2, B39.1, F64.5,B25.2, B84.1, B38.1, B50.4 and B50.1 and which (a) react and bind with extracts from human metastatic mammary carcinoma cells from involved livers but not with liver cell extracts; (b) react and bind with at least one of the mammary carcinoma cell lines, BT-20, MCF-7, ZR-75-1, but not with lung, vulva epidermoid or oral epidermoid and not with rhabdomyosarcoma, fibrosarcoma and melanoma; and (c) do not react with normal cell derived from breast, skin, lung, bone marrow, kidney, spleen and uterus.
Claim 3
Dependent Claim
17 words
Antibodies selected from one member of the group consisting of B6.2, B25.2, B72.3, F25.2, B38.1, and B50.4.
Claim 4
Dependent Claim
17 words
Antibodies selected from one member of the group consisting of B6.2, B25.2, B72.3, F25.2, B38.1, and B50.4.
Claim 5
Dependent Claim
28 words
Antibodies selected from one member of the group consisting of B6.2, B25.2, B38.1, F25.2, B72.3 and B50.4, which bind human mammary carcinoma lines designated BT-20, MCF-7 and ZR-75-1.
Claim 6
Dependent Claim
28 words
Antibodies selected from one member of the group consisting of B6.2, B25.2, B38.1, F25.2, B72.3 and B50.4, which bind human mammary carcinoma lines designated BT-20, MCF-7 and ZR-75-1.
Claim 7
Dependent Claim
19 words
A mouse myeloma cell line selected from the group consisting of ATCC #HB8106, #HB8107, #HB8108, #HB8109, #HB8110, and #HB8111.
Claim 8
Dependent Claim
19 words
A mouse myeloma cell line selected from the group consisting of ATCC #HB8106, #HB8107, #HB8108, #HB8109, #HB8110, and #HB8111.
Claim 9
Independent Claim
77 words
A method of detecting a small number of mammary cancer cells in micro-lesions in thin tissue sections or body fluids by applying monoclonal antibodies selected from the group consisting of monoclonal antibodies designated B6.2, B25.2, B72.3, F25.2, B38.1, and B50.4 to the tissue, adding quantity of goat (anti-mouse Ig) antibody conjugated with peroxidase and fixing with diaminobenzidene and peroxide and staining with hemotoxylin, and after fixing, examining for reddish brown colored cells indicative of mammary cancer cells.
Claim 10
Independent Claim
77 words
A method of detecting a small number of mammary cancer cells in micro-lesions in thin tissue sections or body fluids by applying monoclonal antibodies selected from the group consisting of monoclonal antibodies designated B6.2, B25.2, B72.3, F25.2, B38.1, and B50.4 to the tissue, adding quantity of goat (anti-mouse Ig) antibody conjugated with peroxidase and fixing with diaminobenzidene and peroxide and staining with hemotoxylin, and after fixing, examining for reddish brown colored cells indicative of mammary cancer cells.
Claim 11
Dependent Claim
51 words
In an assay to detect mammary carcinoma cells involving contacting a sample with an antibody under conditions which allow the formation of an antibody antigen complex and measurement of the complex formation, the improvement comprises using monoclonal antibodies selected from the group consisting of B6.2, B25.2, B72.3, F25.2, B38.1, and B50.4.
Claim 12
Dependent Claim
51 words
In an assay to detect mammary carcinoma cells involving contacting a sample with an antibody under conditions which allow the formation of an antibody antigen complex and measurement of the complex formation, the improvement comprises using monoclonal antibodies selected from the group consisting of B6.2, B25.2, B72.3, F25.2, B38.1, and B50.4.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-09-15 | 1990-03-17 | 1990-09-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-09-15 | 1994-03-17 | 1994-09-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-09-15 | 1998-03-17 | 1998-09-16 | $7700.00 | Window Closed / Lapsed |